Compare · AZN vs MPLT
AZN vs MPLT
Side-by-side comparison of AstraZeneca PLC (AZN) and MapLight Therapeutics Inc. (MPLT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and MPLT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $263.10B, about 480.7x MPLT ($547.4M).
- MPLT has been more active in the news (14 items in the past 4 weeks vs 13 for AZN).
- AZN has more recent analyst coverage (25 ratings vs 14 for MPLT).
- Company
- AstraZeneca PLC
- MapLight Therapeutics Inc.
- Price
- -
- -
- Market cap
- $263.10B
- $547.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2025
- News (4w)
- 13
- 14
- Recent ratings
- 25
- 14
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
- Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
- SVP, Group Controller Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,267 units (SEC Form 4)
Latest MPLT
- Chief Discovery Officer Kreitzer Anatol was granted 6,020 units of Voting Common Stock, increasing direct ownership by 3% to 180,926 units (SEC Form 4)
- CAO and Interim CFO Gillis Jonathan was granted 8,242 units of Voting Common Stock, increasing direct ownership by 6% to 152,482 units (SEC Form 4)
- Chief Executive Officer Kroeger Christopher A. was granted 23,145 units of Voting Common Stock, increasing direct ownership by 2% to 1,269,600 units (SEC Form 4)
- General Counsel Hanson Kristopher was granted 7,730 units of Voting Common Stock, increasing direct ownership by 5% to 153,553 units (SEC Form 4)
- Chief Medical Officer Foff Erin Pennock was granted 13,360 units of Voting Common Stock, increasing direct ownership by 4% to 312,261 units (SEC Form 4)
- Chief Scientific Officer Lillie James Woodruff was granted 7,730 units of Voting Common Stock, increasing direct ownership by 4% to 210,110 units (SEC Form 4)
- Large owner Catalyst4, Inc. bought $50,072,000 worth of Voting Common Stock (4,400,000 units at $11.38) (SEC Form 4)
- SEC Form 10-Q filed by MapLight Therapeutics Inc.
- MapLight Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure
- MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update